Cushing Syndrome Clinical Trial Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight's "Cushing Syndrome Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cushing Syndrome Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Cushing Syndrome Pipeline? @ https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Cushing Syndrome Pipeline Report
• In August 2026, Lundbeck announced that the European Commission granted orphan drug designation to asedebart (Lu AG13909), its investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome. A proof-of-concept study is currently evaluating its efficacy and safety in Cushing's disease.
• In August 2026, Lundbeck continued the clinical development of asedebart for Cushing's disease, following preliminary Phase II data presented at ENDO 2026 that supported further investigation of the investigational anti-ACTH antibody.
• DelveInsight's Cushing Syndrome Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Cushing Syndrome treatment.
• The leading Cushing Syndrome Companies such as Stero Therapeutics, Sparrow Pharmaceuticals and others.
• Promising Cushing Syndrome Therapies such as SOM230 LAR 30 mg, Pasireotide LAR, Osilodrostat, SPI-62, Mifepristone, mifepristone, CORT125134 and others.

Want to know which companies are leading innovation in Cushing Syndrome? @ https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Cushing Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Cushing Syndrome Pipeline Report also highlights the unmet needs with respect to the Cushing Syndrome.

Cushing Syndrome Overview
Cushing Syndrome, or hypercortisolism is a hormonal disorder caused by prolonged exposure of the body's tissues to high levels of the hormone cortisol. Causes of Cushing Syndrome are typically divided into two basic categories: those that are adrenocorticotropic hormone (ACTH)-dependent and those that are ACTH-independent. It is a rare disorder and most commonly affects adults aged 20 to 50. The pituitary tumor overproduces ACTH and lacks hypothalamic-pituitary-adrenal (HPA) axis feedback regulation; thus, excessive amounts of cortisol are secreted from the adrenal glands. Prolonged systemic exposure to elevated cortisol levels results in a significant clinical burden in patients with CD due to comorbidities, increased mortality, and impaired health-related quality of life (HRQoL). Cushing's syndrome manifests with various signs and symptoms such as weight gain, particularly in the upper body and face, a round and red face, thin arms and legs, thin and fragile skin that bruises easily, acne, high blood pressure, type 2 diabetes, muscle weakness, and emotional symptoms like depression and anxiety.

Cushing Syndrome Emerging Drugs Profile
• Relacorilant: Corcept Therapeutics
Relacorilant (CORT 125134) is a non-steroidal, selective glucocorticoid receptor II (GR II) antagonist. Upon administration, relacorilant competitively binds to and blocks GRs. This inhibits the activity of GRs, and prevents both the translocation of the ligand-GR complexes to the nucleus and gene expression of GR-associated genes. Corcept is studying relacorilant in a variety of serious disorders, including Cushing's syndrome and adrenal, ovarian and pancreatic cancer. Relacorilant received orphan drug designation in the United States for the treatment of Cushing's syndrome and pancreatic cancer and both the United States and the European Union for the treatment of Cushing's syndrome. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Cushing Syndrome. As per latest updates May 2026, Corcept Therapeutics Incorporated announced it will resubmit its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing's syndrome. Following issuance of its complete response letter by FDA.

If you're tracking ongoing Cushing Syndrome Clinical trials, this press release is a must-read @ https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Cushing Syndrome Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of Cushing Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cushing Syndrome Treatment.
• Cushing Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cushing Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cushing Syndrome market.

Cushing Syndrome Companies
Stero Therapeutics, Sparrow Pharmaceuticals and others.

Cushing Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Cushing Syndrome Products have been categorized under various Molecule types such as,
• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Cushing Syndrome Pipeline Report covers it all @ https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Cushing Syndrome Pipeline Report
• Coverage- Global
• Cushing Syndrome Companies- Stero Therapeutics, Sparrow Pharmaceuticals and others.
• Cushing Syndrome Therapies- SOM230 LAR 30 mg, Pasireotide LAR, Osilodrostat, SPI-62, Mifepristone, mifepristone, CORT125134 and others.
• Cushing Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cushing Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Cushing Syndrome Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Introduction
2. Executive Summary
3. Cushing Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cushing Syndrome- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Relacorilant: Corcept Therapeutics
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Cushing Syndrome Key Companies
21. Cushing Syndrome Key Products
22. Cushing Syndrome- Unmet Needs
23. Cushing Syndrome- Market Drivers and Barriers
24. Cushing Syndrome- Future Perspectives and Conclusion
25. Cushing Syndrome Analyst Views
26. Cushing Syndrome Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.